

For immediate release: 6 December 2004

PLANT HEALTH CARE ANNOUNCES SPECTACULAR RESULTS OF INDEPENDENT FORMONONETIN TESTS

Results show crop yield increases of up to 42%

Plant Health Care plc ("PHC" or the "Company"), a leading provider of natural products for plants and soil, is pleased to announce very encouraging results following independent trials of its newly acquired Formononetin product.

The tests were carried out in the United States on soybean and corn seeds by two independent professional research groups, Beck Hybrid and AgriBusiness Group, and took place in six locations with differing soil and climatic characteristics. Yield increases of corn and soybean crops from seed treated with Formononetin were substantial. In the case of corn, yields improved by up to 25% and soybean yields improved by up to 42%. The benefits were most apparent in those areas where soil quality was low and the weather was poor.

In the UK and Europe where GM farming is currently restricted, the directors believe that the use of Formononetin will allow farmers to produce yields equivalent to or exceeding those of GM crops. Similarly if Formononetin was used in areas of the world where soil quality is particularly poor and rainfall is unpredictable the directors believe the potential for improved growth and increased yields is tremendous. There is scope for broad agricultural application of Formononetin and the positive results shown will help facilitate uptake of the product, as part of Plant Health Care's full product range.

Background: PHC synthesizes Formononetin, a compound originally identified from plant roots that stimulates the growth of mycorrhizal fungi already existing in soil. In natural soil, mycorrhizal fungi are readily available to plants; however, in urban landscapes, degraded lands and most agricultural lands, mycorrhizal fungi are often not present in adequate quantities. Stimulating plant roots with mycorrhizal fungi products can increase the surface area of the root system and improve the health and survivability of plants. The addition of Formononetin to soil or seed has been demonstrated in numerous field trials to increase the yields of row crops such as corn, soybeans and cotton, even when used in very small quantities. PHC acquired the Formononetin synthesis technology through its acquisition of VAMTech LLC last October.

John Brady, Plant Health Care's CEO, said: "We strongly believe that Formononetin can revolutionise the treatment of row crops. We have successfully

been using Formononetin in our products for over three years. These new, independent test results further demonstrate that natural biological-based products can produce results that are equivalent to, or exceed, conventional plant care products. Our test marketing has shown there is huge demand for effective, natural products for row crops. Mass production of Formononetin is already underway and we have initiated field-testing in the US, Australia, Africa and Europe. This product has significant revenue potential and we expect to start generating revenue in 2005, with considerable market penetration in 2006. We are confident that our Formononetin product will make a major impact in the production of commodity row crops in the future."

For further information please contact:

Plant Health Care plc
John Brady, CEO
Tel: 001 603 525 3702

Tavistock Communications
Jeremy Carey/Katy Pratt
Tel: 020 7920 3150
Email: kpratt@tavistock.co.uk